Instructions for Authors | Journal of Neurotherapy


Editors:
Adam Clarke, PhD, Senior Editor

1) MANUSCRIPTS. Manuscripts should be submitted electronically at the Editorial Manager website. The tutorial for submission provides additional information and is available for download HERE. All editorial inquiries should be sent to journal@isnr.org.

2) ORIGINAL ARTICLES. Submission of a manuscript to this journal represents a certification on the part of the author(s) that it is an original work, and that neither this manuscript nor a version of it has been published elsewhere nor is being considered for publication elsewhere.

3) FINANCIAL INTEREST. At the time of submission, authors of research articles will disclose any financial arrangements they may have with a company whose product figures predominantly in the submitted manuscript or with a company making a competitive product. Such information will be held in confidence while the paper is under review. If the paper is selected for publication, the editor will discuss with the author(s) the manner of communicating such information to the readers. Authors of reviews and editorials are expected to have no financial interest in a company or its competitor that makes a product discussed in that review or editorial.

4) SUBMISSION. At the time of electronic submission, the primary authors will identify the person (with address, telephone number, fax number, and e-mail address) responsible for contact during manuscript review. Additional authors are identified during the submission and require a substantial contribution to: (a) conception and design or analysis and interpretation of the data and (b) the writing of the article or critical revision. The names of the authors with their primary academic degree (do not include self designated degrees such as CPA, CLU, BCIA), and the name of any academic, institutional or private practice affiliation should be entered. Any grant support or other support should be listed on the additional comments page.

5) KEYWORDS. Please provide three to ten keywords for index purposes.

6) COPYRIGHT TRANSFER FORM. At the time of submission, all authors must complete a Copyright Transfer Form before the manuscript can be accepted for review. The first page of this form must be scanned and attached with manuscript or faxed to (415) 485-1348 at the time of submission.

7) ABSTRACT. An abstract of not more than 300 words must be provided. The abstract should briefly describe the problem being addressed in the study, how the study was performed, the salient results, and what the authors conclude from the results. It should have the following subsections:
     *Introduction
     *Methods
     *Results
     *Conclusion

8) MANUSCRIPTS. The entire manuscript (Abstract, Introduction, Methods, Results, Discussion) must be double-spaced and attached to your submission at Editorial Manager. Use a one-inch margin on all four sides of your paper. The author is responsible for preparing manuscript copy which is clearly written in acceptable, scholarly English, and which contains no errors of spelling, grammar, or punctuation. Neither the Editor nor the Publisher is responsible for correcting errors of spelling and grammar. References, citations and general style should follow the guidelines set forth in the 2009 (sixth) edition of the Publication Manual of the American Psychological Association. The author is responsible for typing the manuscript in the journal's style and meeting the requirements for publication.

9) DETAILED INFORMATION REQUIRED. Authors must adequately describe their recording methods and parameters. Simply naming the equipment and model number they are using is not sufficient. Details about amplification, filtering, spectral extraction, windowing, and other technical parameters are required. This information is available in manuals, and if not there, should be obtained from the manufacture.

10) PREPARATION OF TABLES, FIGURES, AND ILLUSTRATIONS. Any material that is not textual is considered artwork. Each artwork piece must be attached as a separate file during submission. This includes tables, figures, diagrams, charts, graphs, illustrations, appendices, screen captures, and photos. Figures, diagrams, charts, graphs, illustrations, screen captures, and photos will submitted to an artwork quality check at the time of submission and the author given a report. The Editor will give us this report during consideration of publication and may ask for changes to the artwork. Color art is limited so please submit all figures as black and white unless color is absolutely necessary.

11) MANUSCRIPT REVIEW. After a check of electronic files, manuscripts accepted for review will be assigned to a panel of three consulting editors who will provide a review to the Editors about publication of the manuscript. Authors will be blind to reviewers and reviewers will be blind to each other. Summary results of the reviews and suggestions for revision will be forwarded to the authors. Following favorable review and acceptable revision, the manuscript will be considered for publication and authors notified. If papers are rejected, they will not be returned (unless specifically requested), and authors will he notified, usually within six week of initial review.

12) MANUSCRIPT ACCEPTANCE AND COPYRIGHT. After all revisions have been incorporated and the manuscript has been accepted for publication, the Editor will forward the manuscript and the Copyright Transfer Form to Taylor and Francis for publication in the Journal of Neurotherapy.

13) FINAL SUBMISSION. Editor's galley proofs will be sent to the author for final reading. Only minor changes can be made at this time. The Editor may make small changes in words or phrases only to improve clarity of the manuscript.

14) REPRINTS. The senior author will receive 2 copies of the journal issue and ten complimentary reprints several weeks after the issue is published. Authors are to contact Taylor and Francis about reprints.

15) ETHICS. Authors of manuscripts reporting studies on human participants or animal subjects must confirm and state in the methods section that the reported study was approved by their local internal review board or other appropriate ethics committee. In countries were institutional review boards are not available, the authors must include a statement that the research was conducted in accordance with the Declaration of Helsinki (World Medical Association, 1996).

16) INFORMED CONSENT. All studies involving human participants must obtain informed consent in writing from their participants or caregivers as required by the Declaration of Helsinki.


STANDARDS POLICY FOR ADOPTION TO THE CONFERENCE
AND JOURNAL POLICY AND PROCEDURE MANUALS.

Methods of application are:

1) submission for publication in the Journal of Neurotherapy,
2) submission for presentation at the annual ISNR conference or
3) application for exhibiting as a vendor at the annual ISNR conference:

Any new therapeutic (clinical or nonclinical) applications are welcome to expose themselves in the above 3 ways. However, within 2 years after the first exposure in any of these 3 ways they should have demonstrated either the working mechanism for the proposed application or have demonstrated a proof of efficacy in line with "Level 3: Probably Efficacious" of the ISNR / AAPB guidelines for rating clinical efficacy (see below). It has to be noted that this should at least include data of 1 randomized controlled trial (RCT) using an adequate control group.

We understand that for many procedures it is hard and sometimes impossible to demonstrate the working mechanism. However, if any such treatment really has meaningful effects it is not unrealistic to conduct at least 1 RCT, where patients are randomized to the active treatment and a control group (minimum requirement should be a waiting list control group). Sample sizes of approximately 20-30 patients should already be sufficient to demonstrate clinical efficacy.

This procedure will apply to both new applications and to applications which have been disseminating information in the journal or at the conferences over the last couple of years; however the 2 years will start after this proposal has been formally accepted. (July 11, 2010)

Level 1: Supported only by anecdotal reports and/or case studies in nonpeer reviewed venues. Not empirically supported.

Level 2: Possibly Efficacious. At least one study of sufficient statistical power with well identified outcome measures, but lacking randomized assignment to a control condition internal to the study.

Level 3: Probably Efficacious. Multiple observational studies, clinical studies, wait list controlled studies, and within-subject and intrasubject replication studies that demonstrate efficacy.

Level 4: Efficacious:

In a comparison with a no-treatment control group, alternative treatment group, or sham (placebo) control utilizing randomized assignment, the investigational treatment is shown to be statistically significantly superior to the control condition or the investigational treatment is equivalent to a treatment of established efficacy in a study with sufficient power to detect moderate differences,

The studies have been conducted with a population treated for a specific problem, for whom inclusion criteria are delineated in a reliable, operationally defined manner,

The study used valid and clearly specified outcome measures related to the problem being treated,

The data are subjected to appropriate data analysis,

The diagnostic and treatment variables and procedures are clearly defined in a manner that permits replication of the study by independent researchers, and (f) The superiority or equivalence of the investigational treatment have been shown in at least two independent research settings.

Level 5: Efficacious and Specific. The investigational treatment has been shown to bestatistically superior to credible sham therapy, pill, or alternative bona fide treatment in at least two independent research settings.

Taylor and Francis Transfer of Copyright Form HERE

FOR REVIEWERS ONLY. For a copy of the EM Reviewer Tutorial click HERE.

International Society for Neurofeedback & Research

Executive Director, PMB 114, 1350 Beverly Road, Suite 115, McLean, VA 22101-3633 - (703) 848-1994 - Fax (703) 738-7341